Monday, 31 May 2021

Tuberous Sclerosis Complex (TSC) - Market Outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 


Indication name: Tuberous Sclerosis Complex (TSC)

Tuberous Sclerosis Complex (TSC), Thelansis Epidemiology study reflects there is 1 in 6,000 newborns in the United States. Approximately 40,000 to 80,000 people in the United States have tuberous sclerosis. The prevalence in Europe is estimated to be approximately 1 in 25,000 to 1 in 11,300. As many as 2 million people worldwide are believed to have the disorder.

Competitive landscape of TSC includes country specific approved as well as pipeline therapies. Any asset/ product specific designation or review and Accelerated Approval are being tracked and supplemented with analyst commentary.

KOLs insights of TSC across 8 MM market from center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm and Unmet needs.

TSC Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing , Market Event and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden and pricing scenario, Summary and Insights.

Read more: Tuberous sclerosis complex (TSC) Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2019 To 2030

 

S. N.        Asset        Company        Stage

1        Drug: RAD001        Novartis Pharmaceuticals        Phase 3

2        Drug: Sirolimus 0.2%        Aucta Pharmaceuticals, Inc        Phase 2

3        Drug: NPC-12G gel        Nobelpharma        Phase 3

4        Drug: Ganaxolone        Marinus Pharmaceuticals        Phase 2

5        Drug: Aspirin        Shijiazhuang Yiling Pharmaceutical Co. Ltd        Phase 2

6        Drug: Rapamune        Pfizer        Phase 1

7        Drug: Vatiquinone        PTC Therapeutics        Phase 3

8        Drug: TAK-935        Takeda        Phase 2

9        Drug: Circadin 2/5/10 mg        Neurim Pharmaceuticals Ltd.        Phase 3

10        Drug: TAK-935        Ovid Therapeutics Inc.        Phase 2

No comments:

Post a Comment

Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

  Indication name: Post-traumatic stress disorder (PTSD) Post-traumatic stress disorder (PTSD) – Market outlook, Epidemiology, Market For...